A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction

New England Journal of Medicine

Volumn 325, Issue 6, 1991, Pages 373-381

  Stampfer, Meir J ^a,b   Sacks, Frank M ^a   Salvini, Simonetta ^a   Willett, Walter C ^a,b   Hennekens, Charles H ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B100; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEINS; APOLIPOPROTEINS A; APOLIPOPROTEINS B; CHOLESTEROL; HUMAN; LIPOPROTEINS, HDL CHOLESTEROL; MALE; MIDDLE AGE; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026091744     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199108083250601     Document Type: Article

References (65)

1. Miller N.E., Thelle D.S., Førde O.H., Mjøs O.D. The Tromsø Heart-Study: high-density lipoprotein and coronary heart disease: a prospective case–control study. Lancet 1977; 1:965-968
2. Goldbourt U., Medalie J.H. High density lipoprotein cholesterol and incidence of coronary heart disease — the Israeli Ischaemic Heart Disease Study. Am J Epidemiol 1979; 109:296-308.
3. Enger S.C., Hjermann I., Foss O.P., et al. High density lipoprotein cholesterol and myocardial infarction and sudden coronary death: a prospective case–control study in middle-aged men of the Oslo Study. Artery 1979; 5:170-181
4. Gordon D.J., Probstfield J.L., Garrison P.J., et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989; 79:8-15.
5. Miller N.E. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 1987; 113:589-597
6. Bennett W.I. The drink-a-day lore. New York Times Magazine. January 10, 1988: 55.
7. Jones P.H., Gotto A.M. Jr. Assessment of lipid abnormalities. In: Hurst JW, Schlant RC, Rachley CE, Sonnenblick EH, Wenger NK, eds. The heart: arteries and veins. 7th ed. New York: McGraw-Hill, 1990: 378-84.
8. Grundy S. Disorders of lipids and lipoproteins. In: Stein JH, ed. Internal medicine. 2nd ed. Boston: Little, Brown, 1987: 2035-52.
9. Gofman J.W., Young W., Tandy R. Ischemic heart disease, atherosclerosis, and longevity. Circulation 1966; 34:679-697
10. Ohta T., Hattori S., Murakami M., Nishiyama S., Matsuda I. Age- and sex-related differences in lipoproteins containing apoprotein A-I. Arteriosclerosis 1989; 9:90-95
11. Stampfer M.J., Buring J., Willett W., Rosner B., Eberlein K., Hennekens C.H. The 2×2 factorial design: its application to a randomized trial of aspirin and carotene in U.S. physicians. Stat Med 1985; 4:111-116
12. Steering Committee of the Physicians#x0027; Health Study Research Group. Final report on the aspirin component of the ongoing Physicians#x0027; Health Study. N Engl J Med 1989; 321:129-135
13. World Health Organization. IHD registers: report of the fifth working group. Copenhagen, Denmark: World Health Organization, 1971.
14. Bachorik P.S., Albers J.J. Precipitation methods for quantification of lipoproteins. In: Albers JJ, Segrest JP, eds. Plasma lipoproteins: part B: characterization, cell biology, and metabolism. Vol. 129 of Methods of enzymology. Orlando, Fla.: Academic Press, 1986: 78-100.
15. Satterfield S., Greco P.J., Goldhaber S.Z., et al. Biochemical markers of compliance in the Physicians#x0027; Health Study. Am J Prev Med 1990; 6:290-294
16. SAS Institute Inc. SAS user#x0027;s guide: basics, 1982 edition. Cary, N.C.: SAS Institute, 1982.
17. Idem. SAS user#x0027;s guide: statistics, version 5 edition. Cary, N.C.: SAS Institute, 1985.
18. Storer B.E., Wacholder S., Breslow N.E. Maximum likelihood fitting of general risk models to stratified data. Appl Stat [C] 1983; 32:172-181
19. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 1988; 148:36-69.
20. Mogadam M., Ahmed S.W., Mensch A.H., Godwin I.D. Within-person fluctuations of serum cholesterol and lipoproteins. Arch Intern Med 1990; 150:1645-1648
21. Gordon T., Kannel W.B., Castelli W.P., Dawber T.R. Lipoproteins, cardiovascular disease, and death. Arch Intern Med 1981; 141:1128-1131
22. Castelli W.P., Garrison R.J., Wilson P.W.F., Abbott R.D., Kalousdian S., Kannel W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 1986; 256:2835-2838
23. Musliner T.A., Krauss R.M. Lipoprotein subspecies and risk of coronary disease. Clin Chem 1988; 34:Suppl:B78-B83.
24. Miller N.E., Hammett F., Saltissi S., et al. Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. BMJ 1981; 282:1741-1744
25. Brook J.G., Aviram M., Viener A., Shilansky E., Markiewicz W. High-density lipoprotein subfractions in normolipidemic patients with coronary atherosclerosis. Circulation 1982; 66:923-926
26. Schmidt S.B., Wasserman A.G., Meusing R.A., Schlesselman S.E., Larosa J.C., Ross A.M. Lipoprotein and apolipoprotein levels in angiographically defined coronary atherosclerosis. Am J Cardiol 1985; 55:1459-1462
27. Wallentin L., Sundin B. HDL2 and HDL3 lipid levels in coronary artery disease. Atherosclerosis 1986; 59:131-136
28. Thomas D.J.B., Milne J.R., Stocks J., Ferns G.A.S., Rees R.S.O., Galton D.J. HDL subfractions and angiographically defined coronary artery disease. Br J Clin Pract 1987; 41:741-742
29. Ballantyne F.C., Clark R.S., Simpson H.S., Ballantyne D. High density and low density lipoprotein subfractions in survivors of myocardial infarction and in control subjects. Metabolism 1982; 31:433-437
30. Gidez L.I., Miller G.J., Burstein M., Slagle S., Eder H.A. Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res 1982; 23:1206-1223
31. Laakso M., Voutilainen E., Pyorala K., Sarlund H. Association of low HDL and HDL2 cholesterol with coronary heart disease in noninsulin-dependent diabetes. Arteriosclerosis 1985; 5:653-658
32. Hamsten A., Walldius G., Dahlen G., Johansson B., De Faire U. Serum lipoproteins and apolipoproteins in young male survivors of myocardial infarction. Atherosclerosis 1986; 59:223-235
33. Kauppinen-Makelin R., Nikkila E.A. Serum lipoproteins in patients with myocardial infarction. Atherosclerosis 1988; 74:65-74.
34. Hennekens C.H., Buring J., O#x0027;Connor G.T., et al. Moderate alcohol consumption and risk of myocardial infarction. Circulation 1987; 76:Suppl IV:IV-501.
35. Levy R.I., Brensike J.F., Epstein S.E., et al. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of the NHLBI Type II Coronary Intervention Study. Circulation 1984; 69:325-337
36. Kempen H.J., van Gent C.M., Buytenhek R., Buis B. Association of cholesterol concentrations in low-density lipoprotein, high-density lipoprotein, and high-density lipoprotein subfractions, and of apolipoprotein AI and AII, with coronary stenosis and left ventricular function. J Lab Clin Med 1987; 109:19-26.
37. Albers J.J., Wahl P.W., Cabana G.V., Hazzard W.R., Hoover J.J. Quantitation of apolipoprotein A-I of human plasma high density lipoprotein. Metabolism 1976; 25:633-644
38. Berg K., Borresen A.L. Serum-high-density-lipoprotein and atherosclerotic heart-disease. Lancet 1976; 1:499-501.
39. Albers J.J., Cheung M.C., Hazzard W.R. High-density lipoproteins in myocardial infarction survivors. Metabolism 1978; 27:479-485
40. Avogaro P., Bon G.B., Cazzolato G., Quinci G.B. Are apolipoproteins better discriminators than lipids for atherosclerosis? Lancet 1979; 1:901-903
41. Avogaro P., Bon G.B., Cazzolato G., Rorai E. Relationship between apolipoproteins and chemical components of lipoproteins in survivors of myocardial infarction. Atherosclerosis 1980; 37:69-76.
42. Fager G., Wiklund O., Olofsson S.-O., Wilhelmsson C., Bondjers G. Serum apolipoprotein levels in relation to acute myocardial infarction and its risk factors: apolipoprotein A-I levels in male survivors of myocardial infarction. Atherosclerosis 1980; 36:67-74.
43. Wiklund O., Fager G., Olofsson S.-O., Wilhelmsson C., Bondjers G. Serum apolipoprotein levels in relation to acute myocardial infarction and its risk factors — determination of apolipoprotein D. Atherosclerosis 1980; 37:631-636
44. Fager G., Wiklund O., Olofsson S.-O., Wilhelmsen L., Bondjers G. Multivariate analysis of serum apolipoproteins and risk factors in relation to acute myocardial infarction. Arteriosclerosis 1981; 1:273-279
45. De Backer G., Rosseneu M., Desylpere J.P. Discriminative value of lipids and apoproteins in coronary disease. Atherosclerosis 1982; 42:197-203.
46. Avogaro P., Cazzolato G., Bittolo Bon G., Rorai E., Pontoglio E. Lipoprotein derangements in human atherosclerosis. In: Noseda G, Fragiacomo C, Fumagalli R, Paoletti R, eds. Lipoproteins and coronary atherosclerosis. Amsterdam: Elsevier, 1982: 123-42.
47. Bittolo Bon G., Cazzolato G., Saccardi M., Kostner G.M., Avogaro P. Total plasma apo E and high density lipoprotein apo E in survivors of myocardial infarction. Atherosclerosis 1984; 53:69-75.
48. Franzen J., Fex G. Low serum apolipoprotein A-I in acute myocardial infarction survivors with normal HDL cholesterol. Atherosclerosis 1986; 59:37-42.
49. Leitersdorf E., Gottehrer N., Fainaru M., et al. Analysis of risk factors in 532 survivors of first myocardial infarction hospitalized in Jerusalem. Atherosclerosis 1986; 59:75-93.
50. James R.W., Martin B., Pometta D., Grab B., Suenram A. Apo protein D in a healthy, male population and in male myocardial infarction patients and their male, first-degree relatives. Atherosclerosis 1986; 60:49-53.
51. Johansson S., Bondjers G., Fager G., et al. Serum lipids and apolipoprotein levels in women with acute myocardial infarction. Arteriosclerosis 1988; 8:742-749
52. Berg K., Børresen A.-L., Frick M.H., Dahlen G., Stene J. Serum-H.D.L. in atherosclerotic heart-disease. Lancet 1976; 2:40-41
53. Kladetzky R.C., Assmann G., Walgenbach S., Tauchen P., Helb H.D. Lipoprotein and apolipoprotein values in coronary angiography patients. Artery 1980; 7:191-205.
54. Riesen W.F., Mordasini R., Salzmann C., Theler A., Gurtner H.P. Apolipoproteins and lipids as discriminators of severity of coronary heart disease. Atherosclerosis 1980; 37:157-162
55. Noma A., Yokosuka T., Kitamura K. Plasma lipids and apolipoproteins as discriminators for presence and severity of angiographically defined coronary artery disease. Atherosclerosis 1983; 49:1-7.
56. Maciejko J.J., Holmes D.R., Kottke B.A., Zinsmeister A.R., Dinh D.M., Mao S.J.T. Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease. N Engl J Med 1983; 309:385-389
57. Reardon M.F., Nestel P.J., Craig I.H., Harper R.W. Lipoprotein predictors of the severity of coronary artery disease in men and women. Circulation 1985; 71:881-888
58. Lehtonen A., Marniemi J., Inberg M., Maatela J., Alanen E., Niittymaki K. Levels of serum lipids, apolipoproteins A-I and B and pseudocholinesterase activity and their discriminative values in patients with coronary by-pass operation. Atherosclerosis 1986; 59:215-221
59. Desager J.P., Rousseau M., Riesen W.F., Harvengt C. Limitations of the predictive value for coronary vascular disease of plasma lipids and apoproteins AI, AII, B levels as measured before coronarography in 317 patients. In: de Gennes JL, Polonovski J, Paoletti R, eds. Latent dyslipoproteinemias and atherosclerosis. New York: Raven Press, 1984: 165-74.
60. Parra H., Fievet C., Boniface B., Bertrand M., Duthilleul P., Fruchart J.C. Lipoproteins, apolipoproteins, and coronary artery disease assessed by coronary arteriography. In: de Gennes JL, Polonovski J, Paoletti R, eds. Latent dyslipoproteinemias and atherosclerosis. New York: Raven Press, 1984: 187-97.
61. Kukita H., Hiwada K., Kokubu T. Serum apolipoprotein A-I, A-II and B levels and their discriminative values in relatives of patients with coronary artery disease. Atherosclerosis 1984; 51:261-267
62. Reinhart R.A., Gani K., Arndt M.R., Broste S.K. Apolipoproteins A-I and B as predictors of angiographically defined coronary artery disease. Arch Intern Med 1990; 150:1629-1633
63. Cremer P., Elster H., Labrot B., Kruse B., Muche R., Seidel D. Incidence rates of fatal and nonfatal myocardial infarction in relation to the lipoprotein profile: first prospective results from the Gottingen Risk, Incidence, and Prevalence Study (GRIPS). Klin Wochenschr 1988; 66:Suppl 11:42-49
64. Ishikawa T., Fidge N., Thelle D.S., Førde O.H., Miller N.E. The Tromsø Heart Study: serum apolipoprotein AI concentration in relation to future coronary heart disease. Eur J Clin Invest 1978; 8:179-182
65. Salonen J.T., Salonen R., Penttila I., et al. Serum fatty acids, apolipoproteins, selenium and vitamin antioxidants and the risk of death from coronary artery disease. Am J Cardiol 1985; 56:226-231